Targeting Proteomics to Decipher Biology for the Drug Development Pipeline

Dr. Jeffrey Silva is a highly experienced scientist with a diverse background. He earned his bachelor's degree in chemistry and biochemistry from Merrimack College, and his PhD from Johns Hopkins University, where he researched aflatoxin biosynthesis in Aspergillus. After completing a postdoctoral fellowship at Harvard Medical School, Dr. Silva joined Microbia, a Biotech start-up, where he worked on engineering microbial organisms to overproduce natural products. He then joined Waters Corporation, where he helped develop a novel application for global protein analysis using liquid chromatography and high-resolution mass spectrometry. In 2005, Dr. Silva joined Cell Signaling Technology to lead a Proteomics service group, using unique immuno-affinity capture reagents with LC-MS to probe cellular signaling and protein post-translational modifications for drug discovery and disease biology. More recently, he served as Chief Technology Officer at Adeptrix Corporation, where he developed a microarray technology platform for targeted proteomics. Dr. Silva has now returned to Cell Signaling Technology as a Principal Scientist in the Proteomics group, where he continues to integrate immunoaffinity reagents with mass spectrometry for translational research.